Published in Blood Weekly, February 23rd, 2006
In results prepublished online as a First Edition Paper in the peer-reviewed journal Blood, Quadramet demonstrated broad and synergistic activity when administered in combination with bortezomib in a murine myeloma model. This anticancer activity was characterized by significantly prolonged median survival, rapidly reduced clonogenicity of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.